Did Amy Schumer confirm she used Mounjaro?

Yes. Schumer publicly confirmed on Instagram and her podcast in 2023 that she tried Mounjaro (tirzepatide) for postpartum weight loss. She named the specific medication and described her experience with it, including why she stopped.

Why did Amy Schumer stop taking Mounjaro?

Schumer stated publicly that the gastrointestinal side effects were intolerable. She described nausea and GI symptoms that interfered with her daily life to the point where the weight-loss benefit did not justify continuing.

How much weight do people typically regain after stopping a GLP-1?

Clinical trial data from the STEP 1 extension and SURMOUNT-4 studies show that patients regain approximately two-thirds of lost weight within one year of discontinuation. Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) also tend to revert toward pre-treatment levels.

Can you maintain weight loss after stopping tirzepatide without another medication?

Some patients do, but it requires sustained behavioral changes: caloric monitoring, high daily physical activity (60+ minutes), and often resistance training. The National Weight Control Registry documents the patterns of successful long-term maintainers, though it is worth noting that most participants in that cohort did not lose weight via GLP-1 medications.

Is there a lower dose of Mounjaro that causes fewer side effects?

Tirzepatide is titrated from 2.5 mg up to 15 mg. Lower doses (2.5 mg, 5 mg) produce less GI disturbance but also less weight loss. Some clinicians maintain patients on a lower dose for tolerability, though long-term data on reduced-dose maintenance is limited.

Amy Schumer, Maintenance, and What Happens If You Stop

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Amy Schumer, Maintenance, and What Happens If You Stop Image: HealthRX.com clinical image

The Public Record: What Amy Schumer Actually Said

In late 2023, Amy Schumer confirmed on Instagram and her podcast that she had tried Mounjaro (tirzepatide) as part of her postpartum weight-loss effort. She was direct about the experience: the drug worked for appetite suppression, but the side effects were bad enough that she chose to stop.

Her exact public framing was blunt. She described nausea and GI symptoms that made daily life difficult, and she stated clearly that the tradeoff was not worth it for her. This was not a situation where use is speculated. Schumer confirmed it herself, named the medication, and explained why she quit.

What makes her account clinically relevant is that it maps onto one of the most common real-world outcomes with GLP-1 medications: discontinuation due to adverse effects. In clinical trials, this gets reported as a percentage. In real life, it looks like someone deciding the vomiting isn't worth the weight loss.

Tirzepatide Side Effects: What the Trials Show

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist approved by the FDA initially for type 2 diabetes, later for chronic weight management under the brand name Zepbound.

In the SURMOUNT-1 trial, gastrointestinal adverse events were the most frequently reported side effects across all tirzepatide dose groups:

Nausea: 24% to 33% (dose-dependent)
Diarrhea: 18% to 21%
Vomiting: 8% to 12%
Constipation: 13% to 17%

Treatment discontinuation due to adverse events occurred in 4.3% to 7.1% of tirzepatide patients versus 2.6% on placebo. These are trial numbers, where participants receive structured dose titration and medical monitoring. Real-world dropout rates for GI intolerance are likely higher. Slow titration reduces nausea for many patients, but some individuals (like Schumer, by her own account) find the symptoms persistent regardless of dose adjustment.

The HealthRX.com Medical Team notes that GI side-effect severity varies significantly between individuals. Genetic variation in GLP-1 receptor expression, gastric emptying baseline rates, and individual sensitivity to delayed motility all play roles that current prescribing cannot predict in advance.

What Happens When You Stop a GLP-1: The Regain Data

This is the core clinical question Schumer's public story raises. She stopped. So what does the evidence say happens next?

The most cited discontinuation study is the STEP 1 extension trial, published in Diabetes, Obesity and Metabolism in 2022. Participants who lost an average of 17.3% of body weight on semaglutide 2.4 mg regained approximately two-thirds of that lost weight within one year of stopping the medication. They also saw a return of cardiometabolic improvements (blood pressure, lipids, HbA1c) toward baseline.

For tirzepatide specifically, the SURMOUNT-4 trial published in JAMA in 2023 randomized patients who had already lost weight on tirzepatide to either continue or switch to placebo. The placebo group (i.e., those who stopped) regained roughly 14 percentage points of body weight over 52 weeks, while the continuation group maintained their losses.

These findings are consistent across the GLP-1 class. The mechanism is straightforward: these drugs suppress appetite through central and peripheral pathways. When the drug is withdrawn, appetite returns to its biologically defended set point. Weight regain is not a failure of willpower. It reflects the removal of a pharmacological intervention that was actively suppressing the hormonal drive to eat.

Why People Stop: Beyond "Side Effects"

Schumer's reason for discontinuing was tolerability. But the full picture of GLP-1 discontinuation includes multiple factors that prescribers and patients face:

GI intolerability remains the leading cause of early discontinuation in trials. For tirzepatide, nausea tends to peak during dose-escalation phases and often (but not always) improves at maintenance doses.

Cost and access. Mounjaro carries a list price exceeding $1,000 per month without insurance. Many patients who respond well stop due to coverage gaps, prior authorization denials, or formulary changes. This is a systemic access problem, not a clinical one.

Goal achievement and perceived completion. Some patients reach a target weight and believe they can maintain it without ongoing medication. The SURMOUNT-4 and STEP 1 extension data directly contradict this assumption for most patients.

Muscle loss concerns. GLP-1-mediated weight loss includes lean mass reduction in the range of 25% to 40% of total weight lost. Some patients and clinicians opt to discontinue or reduce dosing to preserve muscle, particularly with concurrent resistance training protocols.

The HealthRX.com Medical Team emphasizes that discontinuation is common and should be planned for, not treated as an afterthought. Any GLP-1 prescribing conversation should include an explicit discussion of what happens after stopping.

Evidence-Based Maintenance Strategies After Discontinuation

For patients who stop GLP-1 therapy (whether by choice, tolerability, or access), the clinical literature supports several maintenance approaches, none of which fully replicate the drug's effect:

Structured caloric monitoring. The National Weight Control Registry data shows that long-term weight maintainers (defined as those keeping off >13 kg for >1 year) share common behaviors: daily self-weighing, consistent breakfast consumption, high levels of physical activity (averaging 60+ minutes daily), and caloric intake monitoring. These are necessary but often insufficient to fully offset GLP-1 withdrawal.

Resistance training for metabolic rate preservation. Lean mass loss during GLP-1 therapy reduces resting metabolic rate. Progressive resistance training during and after drug discontinuation can partially offset this. A 2023 randomized trial found that structured exercise during semaglutide treatment preserved approximately 80% more lean mass compared to semaglutide alone.

Lower-dose or intermittent GLP-1 therapy. Some clinicians prescribe a reduced maintenance dose rather than full cessation. This approach lacks large RCT support but represents an emerging real-world practice pattern. The rationale: partial appetite suppression at lower doses may be tolerable for patients who cannot handle full-dose GI effects.

Alternative pharmacotherapy. For patients who cannot tolerate GLP-1s, options include metformin (modest weight effect of 2-3%), bupropion-naltrexone (Contrave), or phentermine for short-term use. None approach the 15-22% weight loss achievable with tirzepatide at full dose.

The HealthRX.com Medical Team Take

Amy Schumer's public account is clinically useful because it represents a common, under-discussed outcome. The GLP-1 conversation in popular media tends toward two poles: miracle drug or dangerous shortcut. Schumer's experience sits in a more common middle ground, where the drug works pharmacologically but the patient cannot tolerate living with its effects.

From a clinical perspective, her decision to stop was reasonable. GI side effects that impair quality of life are a legitimate reason to discontinue any medication. The more pressing question is what happens next, and here the data is clear: without either ongoing pharmacotherapy or extremely disciplined behavioral intervention, most patients will regain the majority of lost weight within 12 to 18 months.

This is not a character judgment. It is a reflection of how obesity operates as a chronic, biologically defended condition. The same physiological systems that GLP-1 drugs temporarily override (ghrelin signaling, hypothalamic appetite regulation, gastric emptying rate) reassert themselves when the drug is gone.

For patients in Schumer's position, the HealthRX.com Medical Team recommends: discuss a post-discontinuation plan with your prescriber before stopping, consider whether a lower dose might be tolerable, prioritize resistance training to offset lean mass losses, and set realistic expectations that weight stability will require ongoing active management rather than passive maintenance.

At a glance

Status: Amy Schumer publicly confirmed Mounjaro (tirzepatide) use for postpartum weight loss in 2023
Outcome: Discontinued due to intolerable gastrointestinal side effects (confirmed by Schumer herself)
Clinical context: GI intolerability is the #1 reason for early GLP-1 discontinuation in trials
Regain risk: SURMOUNT-4 and STEP 1 extension data show ~two-thirds of lost weight returns within 12 months of stopping
Maintenance options: Behavioral strategies, resistance training, lower-dose GLP-1 therapy, or alternative medications

Frequently asked questions

›